Kymera Therapeutics (KYMR) Short Interest Ratio & Short Volume $30.70 +1.90 (+6.60%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$30.72 +0.02 (+0.07%) As of 04/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Kymera Therapeutics Short Interest DataKymera Therapeutics (KYMR) has a short interest of 7.99 million shares, representing 14.66% of the float (the number of shares available for trading by the public). This marks a 1.91% increase in short interest from the previous month. The short interest ratio (days to cover) is 12.2, indicating that it would take 12.2 days of the average trading volume of 551,023 shares to cover all short positions.Current Short Interest7,990,000 sharesPrevious Short Interest7,840,000 sharesChange Vs. Previous Month+1.91%Dollar Volume Sold Short$218.69 millionShort Interest Ratio12.2 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares64,944,000 sharesShort Percent of Float14.66%Today's Trading Volume1,017,101 sharesAverage Trading Volume551,023 sharesToday's Volume Vs. Average185% Short Selling Kymera Therapeutics? Sign up to receive the latest short interest report for Kymera Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKYMR Short Interest Over TimeKYMR Days to Cover Over TimeKYMR Percentage of Float Shorted Over Time Kymera Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20257,990,000 shares $218.69 million +1.9%14.7%12.2 $27.37 3/15/20257,840,000 shares $269.46 million +3.4%14.4%13.5 $34.37 2/28/20257,580,000 shares $237.63 million +3.3%13.9%13.6 $31.35 2/15/20257,340,000 shares $270.70 million -4.6%13.5%15 $36.88 1/31/20257,690,000 shares $304.45 million -7.9%N/A16 $39.59 1/15/20258,350,000 shares $363.73 million -4.8%N/A17.5 $43.56 12/31/20248,770,000 shares $352.82 million -0.2%N/A20.2 $40.23 12/15/20248,790,000 shares $370.32 million -2.6%N/A20.2 $42.13 11/30/20249,020,000 shares $422.59 million -1.1%N/A20.8 $46.85 11/15/20249,120,000 shares $382.68 million -0.4%N/A21.9 $41.96 Get the Latest News and Ratings for KYMR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/31/20249,160,000 shares $422.92 million +1.0%N/A22.2 $46.17 10/15/20249,070,000 shares $406.34 million +3.0%N/A21.4 $44.80 9/30/20248,810,000 shares $416.98 million -7.2%N/A17.5 $47.33 9/15/20249,490,000 shares $437.30 million +1.5%N/A16.8 $46.08 8/31/20249,350,000 shares $452.17 million -1.3%N/A16.2 $48.36 8/15/20249,470,000 shares $417.06 million -3.9%N/A15.6 $44.04 7/31/20249,850,000 shares $455.07 million -0.2%N/A16.1 $46.20 7/15/20249,870,000 shares $444.15 million +5.2%N/A16.1 $45.00 6/30/20249,380,000 shares $279.99 million -7.5%N/A16.4 $29.85 6/15/202410,140,000 shares $337.56 million +1.5%N/A19.6 $33.29 5/31/20249,990,000 shares $320.78 million +1.2%N/A17.6 $32.11 5/15/20249,870,000 shares $354.73 million -0.4%N/A16.9 $35.94 4/30/20249,910,000 shares $333.17 million +2.2%N/A16.2 $33.62 4/15/20249,700,000 shares $333.58 million +7.1%N/A14.8 $34.39 3/31/20249,060,000 shares $364.21 million +8.8%N/A12 $40.20 3/15/20248,330,000 shares $338.03 million +1.0%N/A10.2 $40.58 2/29/20248,250,000 shares $352.28 million -1.8%N/A9 $42.70 2/15/20248,400,000 shares $314.33 million +1.7%N/A9.4 $37.42 1/31/20248,260,000 shares $270.76 million -4.2%N/A8.9 $32.78 1/15/20248,620,000 shares $242.39 million -4.9%N/A9.3 $28.12 12/31/20239,060,000 shares $230.67 million +4.4%N/A9.4 $25.46 12/15/20238,680,000 shares $226.37 million +12.9%N/A9.9 $26.08 11/30/20237,690,000 shares $159.64 million +3.2%N/A10.3 $20.76 11/15/20237,450,000 shares $134.77 million -8.0%N/A11.2 $18.09 10/31/20238,100,000 shares $94.53 million +10.7%N/A13.9 $11.67 10/15/20237,320,000 shares $92.31 million +0.4%N/A14.2 $12.61 9/30/20237,290,000 shares $101.33 million -1.8%N/A17.9 $13.90 9/15/20237,420,000 shares $141.35 million +3.6%N/A19.7 $19.05 8/31/20237,160,000 shares $136.61 million -2.3%N/A17.1 $19.08 8/15/20237,330,000 shares $143.74 million -3.9%N/A15.5 $19.61Musk’s real agenda in D.C. (Ad)In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…Here’s the full story. 7/31/20237,630,000 shares $166.94 million -5.5%N/A15.3 $21.88 7/15/20238,070,000 shares $178.67 million -0.6%N/A15.5 $22.14 6/30/20238,120,000 shares $186.68 million -2.3%N/A15.2 $22.99 6/15/20238,310,000 shares $229.94 million -10.1%N/A15.5 $27.67 5/31/20239,240,000 shares $272.03 million -2.0%N/A18.8 $29.44 5/15/20239,430,000 shares $281.96 million -2.0%21.3%20.8 $29.90 4/30/20239,620,000 shares $303.41 million -0.2%21.7%21.4 $31.54 4/15/20239,640,000 shares $316.77 million +0.5%21.8%21.4 $32.86 3/31/20239,590,000 shares $284.15 million +2.0%21.7%18.6 $29.63 3/15/20239,400,000 shares $292.62 million -0.6%21.3%17.6 $31.13 2/28/20239,460,000 shares $296.85 million -0.7%21.4%13.2 $31.38 2/15/20239,530,000 shares $314.49 million -1.1%21.7%13.1 $33.00 1/31/20239,640,000 shares $360.34 million +2.4%21.9%12.9 $37.38 1/15/20239,410,000 shares $325.02 million +4.6%21.4%12.3 $34.54 12/30/20229,000,000 shares $224.64 million +11.8%20.5%11.7 $24.96 12/15/20228,050,000 shares $224.60 million +9.8%18.4%10.6 $27.90 11/30/20227,330,000 shares $212.42 million -7.0%16.9%11.7 $28.98 11/15/20227,880,000 shares $236.64 million -5.6%18.1%12.3 $30.03 10/31/20228,350,000 shares $253.34 million +8.4%19.3%12.6 $30.34 10/15/20227,700,000 shares $169.40 million +1.9%18.0%11.6 $22.00 9/30/20227,560,000 shares $164.58 million +10.2%17.9%11.7 $21.77 9/15/20226,860,000 shares $197.29 million +7.7%16.2%9.9 $28.76 8/31/20226,370,000 shares $180.08 million +7.4%15.1%8.9 $28.27 8/15/20225,930,000 shares $200.08 million -3.3%14.8%8.2 $33.74 7/31/20226,130,000 shares $135.04 million -4.1%15.3%8 $22.03 7/15/20226,390,000 shares $148.44 million +10.0%16.0%8 $23.23 6/30/20225,810,000 shares $114.40 million +16.9%14.5%7.5 $19.69 6/15/20224,970,000 shares $70.47 million +1.0%12.4%6.8 $14.18 5/31/20224,920,000 shares $70.21 million -0.2%12.3%7.6 $14.27 5/15/20224,930,000 shares $85.98 million +42.5%12.3%8.4 $17.44 4/30/20223,460,000 shares $108.47 million +6.1%8.7%6.8 $31.35 4/15/20223,260,000 shares $124.01 million +7.6%8.2%8 $38.04 3/31/20223,030,000 shares $128.23 million -3.5%7.6%7.4 $42.32 3/15/20223,140,000 shares $111.97 million +11.4%9.4%8 $35.66 2/28/20222,820,000 shares $112.12 million +8.1%8.4%7.2 $39.76 2/15/20222,610,000 shares $114.14 million +13.5%7.8%6.8 $43.73 1/31/20222,300,000 shares $96.60 million +12.2%7.5%6.4 $42.00 1/15/20222,050,000 shares $84.19 million +3.5%6.0%6.1 $41.07 12/31/20211,980,000 shares $125.71 million +17.2%5.8%7 $63.49 12/15/20211,690,000 shares $93.71 million -0.6%4.9%5.9 $55.45 11/30/20211,700,000 shares $94.38 million +13.3%5.0%5.6 $55.52 11/15/20211,500,000 shares $91.95 million +4.9%4.4%4.9 $61.30 10/29/20211,430,000 shares $84.20 million +0.7%4.4%4.4 $58.88 10/15/20211,420,000 shares $81.22 million -13.9%4.3%4.3 $57.20 9/30/20211,650,000 shares $96.92 million +8.6%5.0%4.5 $58.74 9/15/20211,520,000 shares $98.78 million -10.1%4.6%3.1 $64.99 8/31/20211,690,000 shares $105.02 million -15.5%5.1%3.5 $62.14 8/13/20212,000,000 shares $107.88 million -2.9%6.2%4.2 $53.94 7/30/20212,060,000 shares $123.97 million +5.6%7.1%4.2 $60.18 7/15/20211,950,000 shares $93.83 million -17.4%6.7%4 $48.12Musk’s real agenda in D.C. (Ad)In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of America…Here’s the full story. 6/30/20212,360,000 shares $114.46 million +30.4%8.1%4.8 $48.50 6/15/20211,810,000 shares $88.40 million -7.7%6.9%4.7 $48.84 5/28/20211,960,000 shares $94.26 million -8.8%7.4%4.5 $48.09 5/14/20212,150,000 shares $97.55 million -9.3%8.2%5 $45.37 4/30/20212,370,000 shares $108.31 million +3.0%9.6%6 $45.70 4/15/20212,300,000 shares $83.47 million +6.5%9.4%6.4 $36.29 3/31/20212,160,000 shares $78.68 million +100.0%8.9%6.7 $36.43 3/15/20211,080,000 shares $60.59 million +3.9%4.4%3.6 $56.10 2/26/20211,040,000 shares $51.58 million -13.3%4.3%4.9 $49.60 2/12/20211,200,000 shares $82.88 million +0.8%5.2%6.5 $69.07 1/29/20211,190,000 shares $76.01 million +8.2%5.2%6.9 $63.87 1/15/20211,100,000 shares $89.43 million No Change4.8%6.7 $81.30 KYMR Short Interest - Frequently Asked Questions What is Kymera Therapeutics' current short interest? Short interest is the volume of Kymera Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 7,990,000 shares of KYMR short. 14.66% of Kymera Therapeutics' shares are currently sold short. Learn More on Kymera Therapeutics' current short interest. What is a good short interest ratio for Kymera Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KYMR shares currently have a short interest ratio of 12.0. Learn More on Kymera Therapeutics's short interest ratio. Which institutional investors are shorting Kymera Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Kymera Therapeutics: Group One Trading LLC, Citadel Advisors LLC, Jane Street Group LLC, Susquehanna International Group LLP, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Kymera Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.66% of Kymera Therapeutics' floating shares are currently sold short. Is Kymera Therapeutics' short interest increasing or decreasing? Kymera Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,990,000 shares, an increase of 1.9% from the previous total of 7,840,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Kymera Therapeutics' short interest compare to its competitors? 14.66% of Kymera Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Kymera Therapeutics: Lantheus Holdings, Inc. (9.67%), Revolution Medicines, Inc. (10.47%), BridgeBio Pharma, Inc. (15.15%), Legend Biotech Co. (5.98%), TG Therapeutics, Inc. (17.60%), Blueprint Medicines Co. (8.82%), Sarepta Therapeutics, Inc. (6.92%), Axsome Therapeutics, Inc. (13.61%), Nuvalent, Inc. (13.24%), Verona Pharma plc (12.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Kymera Therapeutics stock? Short selling KYMR is an investing strategy that aims to generate trading profit from Kymera Therapeutics as its price is falling. KYMR shares are trading up $1.90 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kymera Therapeutics? A short squeeze for Kymera Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KYMR, which in turn drives the price of the stock up even further. How often is Kymera Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KYMR, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Lantheus Short Interest Data Revolution Medicines Short Interest Data BridgeBio Pharma Short Interest Data Legend Biotech Short Interest Data TG Therapeutics Short Interest Data Blueprint Medicines Short Interest Data Sarepta Therapeutics Short Interest Data Axsome Therapeutics Short Interest Data Nuvalent Short Interest Data Verona Pharma Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KYMR) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
